tetrahydro-1H-pyrrolo<2,1-c><1,4>oxazin-4(3H)-one | 101250-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: tetrahydro-1H-pyrrolo<2,1-c><1,4>oxazin-4(3H)-one
• 英文别名: Tetrahydro-1H-pyrrol[2,1-c][1,4]oxazin-4-(3H)-one；tetrahydro-1H-pyrrolo[2,1-c][1,4]oxazin-4-(3H)-one；Tetrahydropyrrolo[2,1-c][1,4]oxazin-4-one；6,7,8,8a-tetrahydro-1H-pyrrolo[2,1-c][1,4]oxazin-4-one
• CAS: 101250-37-7
• 化学式: C₇H₁₁NO₂
• 分子量: 141.17
• InChiKey: DQMVZJPBUAQCMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tetrahydro-1H-pyrrolo<2,1-c><1,4>oxazin-4(3H)-one 在 盐酸 、 sodium hydroxide 作用下， 生成 (S)-phenylmethyl 2-<(carboxymethoxy)methyl>-1-pyrroldinecarboxylate
  参考文献：
  名称：

  Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents

  摘要：

  A number of peptides and modified peptides were synthesized and studied for their ability to reverse electroconvulsive shock-induced amnesia in rodents. A few of these peptides were selected for secondary evaluation in tests of short-term memory in rats and aged rhesus monkeys. A number of the peptides and modified peptides were active in the amnesia reversal test. In selected secondary tests, however, the chosen compounds failed to show significant activity in enhancing memory. New methods for preparing methyleneamino and methyleneoxy isosteres of peptides are reported. Other modified peptides also included methylenethio, methylenesulfonyl, and ethylene isosteres in place of the normal peptide amide bond.

  DOI：

  10.1021/jm00156a012
• 作为产物：
  描述：

  2-Chloro-1-(2-hydroxymethyl-pyrrolidin-1-yl)-ethanone 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 以46%的产率得到tetrahydro-1H-pyrrolo<2,1-c><1,4>oxazin-4(3H)-one
  参考文献：
  名称：

  Modified di- and tripeptides of the C-terminal portion of oxytocin and vasopressin as possible cognition activation agents

  摘要：

  A number of peptides and modified peptides were synthesized and studied for their ability to reverse electroconvulsive shock-induced amnesia in rodents. A few of these peptides were selected for secondary evaluation in tests of short-term memory in rats and aged rhesus monkeys. A number of the peptides and modified peptides were active in the amnesia reversal test. In selected secondary tests, however, the chosen compounds failed to show significant activity in enhancing memory. New methods for preparing methyleneamino and methyleneoxy isosteres of peptides are reported. Other modified peptides also included methylenethio, methylenesulfonyl, and ethylene isosteres in place of the normal peptide amide bond.

  DOI：

  10.1021/jm00156a012

文献信息

• MINERALOCORTICOID RECEPTOR ANTAGONISTS AND METHODS OF USE
  申请人：GAVARDINAS Konstantinos

  公开号：US20090163472A1

  公开（公告）日：2009-06-25

  The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本发明提供了一种式(I)化合物： 或其药学上可接受的盐；包含式(I)化合物与适宜载体、稀释剂或赋形剂的药物组合物；以及治疗生理障碍，特别是充血性心力衰竭、高血压、糖尿病肾病或慢性肾病的方法，包括给予式(I)化合物或其药学上可接受的盐。
• Modified tripeptides
  申请人：Warner-Lambert Company

  公开号：US04596819A1

  公开（公告）日：1986-06-24

  Modified oxytocin-vasopressin di- or tri-peptides wherein an amide group is replaced by a group selected from ##STR1## --CH.sub.2 NH--, --CH.sub.2 O--, --CH.sub.2 S--, --CH.sub.2 SO--, --CH.sub.2 SO.sub.2 --, --CH.sub.2 CH.sub.2 -- and --CH.dbd.CH-- are described as well as methods for their manufacture, pharmaceutical compositions and methods for treatment, especially of cognitive disorders, depression, morphine dependency and parkinsonism by adjunctive therapy.

  本发明涉及一种改性催产素-加压素二肽或三肽，其中酰胺基团被选自##STR1## --CH.sub.2 NH--, --CH.sub.2 O--, --CH.sub.2 S--, --CH.sub.2 SO--, --CH.sub.2 SO.sub.2 --, --CH.sub.2 CH.sub.2 -- 和 --CH.dbd.CH-- 的基团所取代。本发明还涉及其制备方法、制药组合物以及通过辅助治疗治疗认知障碍、抑郁症、吗啡依赖和帕金森症的方法。
• 6H-dibenzo[B,E]oxepine derived nonsteroidal mineralocorticoid receptor antagonists
  申请人：Eli Lilly and Company

  公开号：EP2537845A1

  公开（公告）日：2012-12-26

  The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  本发明提供了一种式 (I) 的化合物： 或其药学上可接受的盐；药物组合物，包括与合适的载体、稀释剂或赋形剂结合的式 (I) 化合物；以及治疗生理紊乱，特别是充血性心力衰竭、高血压、糖尿病肾病或慢性肾病的方法，包括施用式 (I) 化合物或其药学上可接受的盐。
• 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS
  申请人：ELI LILLY AND COMPANY

  公开号：EP2235007B1

  公开（公告）日：2012-10-31
• 6H-DIBENZO[B,E]OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS
  申请人：Eli Lilly and Company

  公开号：EP2537845B1

  公开（公告）日：2014-03-19